Gastroenterology · Ulcerative ColitisTrial Updateclinicalmid-term

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Pfizer47 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 6:03:15 AM

Assessment confidence: 91% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 3 trial of tofacitinib in pediatric ulcerative colitis is significant as it may establish a new treatment option in a previously underserved population. Success could enhance Pfizer's market position and influence competitive dynamics in the gastroenterology space. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 18 ranked evidence items (17 high-relevance).

Strategic Assessment

Success in this trial may expand Pfizer's portfolio in pediatric gastroenterology, enhancing its competitive edge against other treatments in this space. The strongest clinical anchor is Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis (ClinicalTrials.gov), entity match (pfizer); patient population match (pediatric). In Gastroenterology · Ulcerative Colitis, 7 regulatory and 2 competitive items passed relevance filtering for Pfizer.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — entity match (pfizer). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial could position tofacitinib as a key treatment option for pediatric patients, potentially impacting the market share of existing therapies for ulcerative colitis.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Sponsor/company relevance (Pfizer); Patient population match (pediatric). The trial's outcomes will be critical for regulatory approval in the pediatric population, which may set a precedent for future pediatric indications of similar therapies.

Key Risks

Elevated medium regulatory exposure for Pfizer could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If successful, tofacitinib could capture significant market share among pediatric patients, potentially displacing existing therapies and driving revenue growth for Pfizer.
Lead sponsor: Pulmovant, Inc.. This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.
Success in this trial may expand Pfizer's portfolio in pediatric gastroenterology, enhancing its competitive edge against other treatments in this space.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's primary endpoint results and any updates on patient enrollment and safety outcomes over the study duration.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Sponsor/company relevance (Pfizer); Patient population match (pediatric)
FDA document
View source
FDA AP — MALARONE PEDIATRIC (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Pfizer); Patient population match (pediatric)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Entity match (tofacitinib); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Entity match (tofacitinib); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Entity match (tofacitinib); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Entity match (tofacitinib); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Entity match (tofacitinib); Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (pfizer); Patient population match (pediatric)
FDA document
View source
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer); Patient population match (pediatric)
FDA document
View source
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (ulcerative colitis)
FDA document
View source
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (ulcerative colitis)
FDA document
View source
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
ClinicalTrials.govhigh relevance
Entity match (ulcerative colitis)
FDA document
View source
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Entity match (pfizer)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)

Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pfizer
Tofacitinib
Ulcerative Colitis
Gastroenterology

Commercial impact

high

If successful, tofacitinib could capture significant market share among pediatric patients, potentially displacing existing therapies and driving revenue growth for Pfizer.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory approval in the pediatric population, which may set a precedent for future pediatric indications of similar therapies.

What to watch

Monitor the trial's primary endpoint results and any updates on patient enrollment and safety outcomes over the study duration.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.